Press releases arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

November 5, 2026

Affibody to Participate in the London Life Sciences Week

Stockholm, Sweden, November 5, 2026. Affibody Medical AB (“Affibody”), a clinical stage biotechnology company developing next generation radiopharmaceuticals, today announced that management will participate in the London Life Sciences...

Regulatory

November 2, 2026

New Izokibep Data in Psoriatic Arthritis to be Presented at ACR Convergence 2026

Stockholm, Sweden, November 2, 2026. Affibody Medical AB (“Affibody”) today announced new analyses from its global Phase 2b/3 study of the next generation IL-17A inhibitor izokibep in psoriatic arthritis...

Regulatory

October 14, 2026

Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026

Stockholm, Sweden, October 14, 2026. Affibody AB (“Affibody”) today announced a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October...

Regulatory

October 7, 2026

Affibody to Participate in the 6th Annual Needham Private Biotech & Medtech Company Virtual 1×1 Forum

Stockholm, Sweden, October 7, 2026. Affibody Medical AB (“Affibody”), a clinical stage biotechnology company developing next generation radiopharmaceuticals, today announced that management will participate in the 6th Annual Needham...

Regulatory

September 30, 2026

Affibody Announces New Izokibep Data at EADV 2026 Demonstrating Efficacy Across Patient Subgroups and Stringent Clinical Endpoints

Stockholm, Sweden, September 30, 2026. Affibody AB (“Affibody”) today announced new analyses from its global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS),...

Regulatory

August 27, 2026

Affibody to Participate in Upcoming Healthcare Investor Conferences

Stockholm, Sweden, August 27, 2026. Affibody AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an...

Regulatory

May 28, 2026

First Patient Dosed in Part B of Phase 1 Study with Affibody’s Radioligand Therapy Candidate ABY-271 in HER2-positive Metastatic Breast Cancer

Stockholm, Sweden, May 28, 2026. Affibody AB (“Affibody”) today announced that the first patient has been dosed in part B of a Phase 1 clinical study with the company’s...

Regulatory

May 27, 2026

Affibody Presents First-in-Human Clinical Imaging Data with ABY-271 in HER2-positive Metastatic Breast Cancer at SNMMI 2026

Stockholm, Sweden, May 27, 2026. Affibody AB (“Affibody”) today announced that initial first-in-human clinical imaging data from the ongoing Phase 1 study with the HER2-targeting Radioligand Therapy (RLT) candidate...

Regulatory

May 25, 2026

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 25, 2026 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...